Friday, December, 06, 2019 04:06:16

Contribution By Paroma Bhattacharya


Santhera announces its intent to file application for CMA for Puldysa®

The authorized regulators have acknowledged the choice of pathway for conditional marketing authorization. Santhera Pharmaceuticals has announced its intention of filing an application with European Medicines Agency (EMA) for Conditional Marketing Authorization (CMA) for Puldysa® (idebenone) to treat respiratory dysfunction in Duchenne muscular dystrophy (DMD). …